Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors.
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
/ adverse effects
B7-H1 Antigen
/ antagonists & inhibitors
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Immune Checkpoint Inhibitors
/ adverse effects
Ipilimumab
/ administration & dosage
Kaplan-Meier Estimate
Lung Neoplasms
/ drug therapy
Male
Melanoma
/ drug therapy
Molecular Targeted Therapy
Neoplasm Proteins
/ antagonists & inhibitors
Nivolumab
/ administration & dosage
Pilot Projects
Progression-Free Survival
Prospective Studies
T-Lymphocytes
/ drug effects
T-Lymphocytes, Regulatory
/ drug effects
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 07 2021
28 07 2021
Historique:
received:
10
12
2020
accepted:
17
06
2021
entrez:
29
7
2021
pubmed:
30
7
2021
medline:
4
11
2021
Statut:
epublish
Résumé
Advances in cancer immunology have increased the use of immune checkpoint inhibitors in clinical practice, however not all patients respond, and treatment can have severe side-effects. Blood-based immunological biomarkers are an attractive method for predicting which patients will respond to therapy, however, reliable biomarkers for immune checkpoint blockade are lacking. This study aimed to identify patients before or early in treatment who would best respond to PD-1 inhibitors. We hypothesised that higher baseline PD-L1 and/or PD-1 on peripheral blood T cells could predict radiological response to PD-1 inhibitors. This pilot prospective cohort study assessed 26 patients with melanoma or non-small cell lung cancer, treated with pembrolizumab, nivolumab, or nivolumab/ipilimumab combined. Response was assessed by RECIST 1.1. Peripheral blood lymphocytes collected at baseline, after one cycle, 10 weeks and at discontinuation of therapy were analysed by flow cytometry. Patients with a higher proportion of PD-L1
Identifiants
pubmed: 34321489
doi: 10.1038/s41598-021-93479-z
pii: 10.1038/s41598-021-93479-z
pmc: PMC8319434
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
B7-H1 Antigen
0
CD274 protein, human
0
Immune Checkpoint Inhibitors
0
Ipilimumab
0
Neoplasm Proteins
0
Nivolumab
31YO63LBSN
pembrolizumab
DPT0O3T46P
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
15312Informations de copyright
© 2021. The Author(s).
Références
Clin Cancer Res. 2019 Apr 1;25(7):2144-2154
pubmed: 30647082
Cell. 2017 Sep 7;170(6):1120-1133.e17
pubmed: 28803728
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Lancet Oncol. 2015 Aug;16(8):908-18
pubmed: 26115796
Immunity. 2007 Jul;27(1):111-22
pubmed: 17629517
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
NPJ Genom Med. 2017;2:
pubmed: 28819565
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2729-34
pubmed: 19202079
Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14987-92
pubmed: 18818309
Oncotarget. 2017 Oct 4;8(52):90123-90131
pubmed: 29163815
Semin Cancer Biol. 2018 Oct;52(Pt 2):269-277
pubmed: 29782924
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Nat Commun. 2017 Sep 19;8(1):592
pubmed: 28928380
Lancet Oncol. 2016 Dec;17(12):e542-e551
pubmed: 27924752
Immunity. 2016 May 17;44(5):955-72
pubmed: 27192563
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Sci Rep. 2019 Feb 22;9(1):2636
pubmed: 30796310
Nat Commun. 2018 Dec 18;9(1):5361
pubmed: 30560866
Cancer Lett. 2018 Feb 1;414:166-173
pubmed: 29155348
J Immunother Cancer. 2019 Feb 20;7(1):50
pubmed: 30786924
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
pubmed: 24714771
J Immunother Cancer. 2019 Oct 26;7(1):278
pubmed: 31655605
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Nat Commun. 2018 Jul 26;9(1):2922
pubmed: 30050125
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Oncotarget. 2017 Oct 24;8(60):101994-102005
pubmed: 29254220
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Nature. 2017 May 4;545(7652):60-65
pubmed: 28397821
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Lung Cancer. 2016 Mar;93:9-16
pubmed: 26898608
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446
J Exp Med. 2017 Apr 3;214(4):895-904
pubmed: 28302645
Immunity. 2009 Jun 19;30(6):899-911
pubmed: 19464196